3. Frequently Asked Questions – FMT Patient Edition
Plain answers to the questions patients most often ask before, during, and after FMT, pointing you toward the fuller chapters for detail.
This section answers the questions most frequently asked by patients before, during, and after FMT treatment. For clinical detail on any topic, refer to the corresponding chapter of this guide.
What exactly is FMT, and how does it work?
FMT – fecal microbiota transplantation – involves transferring processed stool material from a healthy, thoroughly screened donor into your gastrointestinal tract. The goal is not to treat a symptom directly but to restore a diverse, functional microbial community to a gut that has lost ecological balance. The donor’s microbiota colonises your gut, restoring colonisation resistance, metabolic function, and immune regulation.
Is FMT safe?
FMT has an established safety record for recurrent Clostridioides difficile infection, where it is considered standard of care in many countries. All donors undergo rigorous screening for infectious diseases, antibiotic-resistant organisms, and metabolic risk factors. Serious adverse events are rare but possible; they are discussed in detail in Chapter II.6. You will be monitored closely throughout treatment.
How long does treatment take?
This depends on your indication, your response to the compatibility assessment, and how your gut ecology evolves during treatment. The MicroBiome Bank protocol spans four phases: compatibility assessment (Phase 0, up to 32 days), induction (Phase 1, colonoscopic or intensive capsule delivery), consolidation (Phase 2, weeks 2–6), and step-down (Phase 3, gradual reduction over months). Most patients complete the active protocol within 3–6 months.
What is the compatibility assessment, and why does it exist?
The compatibility assessment (Phase 0) is a structured pre-treatment phase in which you receive capsules from four different donor preparations over four consecutive 8-day cycles. The biological and symptomatic response to each donor is recorded using the Food and Symptom Diary. This data informs donor selection for the induction phase, maximising the probability of engraftment. This protocol is a proprietary pilot method developed at MicroBiome Bank and has not yet been independently validated by external randomised controlled trial.
Do I have to know who my donor is?
No. Donor identity is confidential. You will receive information about the donor’s general health profile, screening results, and relevant characteristics, but personal identifying information is not disclosed. This protects both donor and recipient privacy.
What should I eat before and during treatment?
Diet is one of the most powerful variables you control during FMT. Chapter III provides detailed guidance. The general principles: before FMT, avoid unnecessary antibiotics, ultra-processed foods, and high-sugar diets. During consolidation, prioritise dietary fibre (target 25–35g daily), fermented foods, and Mediterranean-pattern eating. Avoid factors that destabilise the new microbial community – especially antibiotics, unless clinically essential.
Can I take my regular medications during FMT?
Most medications can be continued. However, some – particularly antibiotics, proton pump inhibitors, immunosuppressants, and certain antifungals – may reduce engraftment or alter treatment response. Chapter VII covers all major medication categories. Discuss any medication changes with your clinical team before making them.
What symptoms are normal after FMT?
In the first week, most patients experience some combination of: altered bowel frequency or consistency, bloating, transient abdominal cramping, mild fatigue, and possible low-grade temperature. These reflect the ecological competition between donor and recipient microbial communities – the 3–5 day ‘flare’ period is expected and does not indicate treatment failure. Chapter II.4 details normal vs. concerning responses.
What symptoms should prompt me to contact my clinical team immediately?
Contact your clinical team same day or attend emergency services immediately if you experience: fever above 38.5°C, severe abdominal pain that does not resolve within 2–3 hours, blood in stool (unless you have a known condition explaining this), signs of dehydration (dizziness, no urination for 8+ hours), difficulty breathing, or any symptom that feels severe or is rapidly worsening. Chapter II.6 provides a full tiered warning sign reference.
How do I know if the FMT is working?
Progress indicators vary by indication. For C. difficile, the primary marker is resolution of recurrent diarrhoea. For IBD and other conditions, improvement may be gradual and multidimensional: changes in stool consistency, reduced symptom frequency, improved energy, and quality-of-life scores. The Food and Symptom Diary (Chapter XVI-3) is your primary tracking tool. Your clinical team will assess microbiota composition at defined intervals.
Can FMT cure my condition permanently?
For recurrent C. difficile, long-term remission rates are high (80–92% after a single course, higher after repeat treatment). For other conditions, FMT is more accurately described as an ecological reset that creates conditions for sustained improvement – the maintenance of that improvement depends on ongoing lifestyle, diet, and exposome management. Long-term outcomes for non-CDI indications are an active area of research.
Will I need to change my lifestyle permanently?
The exposome chapters (III–XIII) describe the factors that shape your gut microbiota on an ongoing basis. The goal is not to impose a rigid protocol but to identify the changes – particularly in diet, sleep, stress, and antibiotic use – that most significantly support microbiota stability. The Priority Guide (Chapter XVI-5) identifies the highest-impact changes for each phase of treatment.
Is FMT effective for my specific condition?
Evidence strength varies considerably by indication. For recurrent C. difficile: very strong (multiple RCTs, standard of care in many countries). For ulcerative colitis: moderate (RCT evidence shows benefit in some patients; response rates variable). For other conditions including IBS, metabolic disease, neurological conditions, and autoimmune disease: early-stage or experimental. Chapter XIV.G explains how to interpret evidence strength for different study types.
Can FMT be repeated if the first course does not work?
Yes. For C. difficile, repeat FMT is standard practice when initial treatment does not produce sustained remission. For other indications, repeat treatment decisions are made individually based on response data, microbiota composition, and clinical assessment. The compatibility assessment data from Phase 0 informs the selection of a different donor if needed.